Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma

被引：0
|
作者：
Wenjie Liu [1 ]
Yuting Fang [1 ]
Chao Zhang [2 ]
Midan Xiang [1 ]
Lijuan Qi [3 ]
Aijiang Su [2 ]
Yongkun Sun [1 ]
机构：
[1] Chinese Academy of Medical Sciences and Peking Union Medical College,National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center
[2] Beijing Chaoyang District Sanhuan Cancer Hospital,Department of Medical Oncology
[3] Chinese Academy of Medical Sciences,National Cancer Center, National Clinical Research Center for Cancer/Hebei Cancer Hospital
来源：
BMC Gastroenterology | / 25卷 / 1期
关键词：
Metastatic pancreatic ductal adenocarcinoma; NALIRIFOX; Nab-paclitaxel and gemcitabine; Cost-effectiveness;
D O I：
10.1186/s12876-025-03867-2
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cost-effectiveness of nab-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer
    Chiorean, E. Gabriela
    Whiting, Scott
    Binder, Gary
    Dranitsaris, George
    Manax, Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [2] Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan
    Morimoto, Kosuke
    Moriwaki, Kensuke
    Kaneyasu, Takako
    Nakayama, Hitomi
    Shimozuma, Kojiro
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 54 - 60
  • [3] Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china
    Cui, Jiujie
    Zhang, Xiaochen
    Qu, Shuli
    Wang, Liwei
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (04) : 691 - 697
  • [4] Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial
    Bekaii-Saab, Tanios
    Okusaka, Takuji
    Goldstein, David
    Oh, Do-Youn
    Ueno, Makoto
    Ioka, Tatsuya
    Fang, Weijia
    Anderson, Eric C.
    Noel, Marcus S.
    Reni, Michele
    Choi, Hye Jin
    Goldberg, Jonathan S.
    Oh, Sang Cheul
    Li, Chung-Pin
    Tabernero, Josep
    Li, Jian
    Foos, Emma
    Oh, Cindy
    Van Cutsem, Eric
    ECLINICALMEDICINE, 2023, 58
  • [5] Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma
    Nebot-Villacampa, Maria-Jose
    Zafra-Morales, Ricardo
    Alfaro-Olea, Ascension
    Marin-Gorricho, Raquel
    Casajus-Navasal, Andrea
    Uriarte-Pinto, Moises
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (03) : 603 - 611
  • [6] Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis
    Takashi Kaneko
    Kazuya Sugimori
    Yuichiro Tozuka
    Taito Fukushima
    Kazuya Okada
    Hiroyuki Oka
    Hiroshi Okazaki
    Shin Maeda
    Clinical Journal of Gastroenterology, 2019, 12 : 484 - 489
  • [7] Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis
    Kaneko, Takashi
    Sugimori, Kazuya
    Tozuka, Yuichiro
    Fukushima, Taito
    Okada, Kazuya
    Oka, Hiroyuki
    Okazaki, Hiroshi
    Maeda, Shin
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2019, 12 (05) : 484 - 489
  • [8] Efficacy and safety of sitagliptin, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC)
    Zhou, Tianxing, Sr.
    Wang, Xiuchao, Sr.
    Yang, Chao, Sr.
    Yu, Jun, Sr.
    Hao, Jihui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
    Nichetti, Federico
    Rota, Simone
    Ambrosini, Paolo
    Pircher, Chiara
    Gusmaroli, Eleonora
    Busset, Michele Droz Dit
    Pusceddu, Sara
    Sposito, Carlo
    Coppa, Jorgelina
    Morano, Federica
    Pietrantonio, Filippo
    Di Bartolomeo, Maria
    Mariani, Luigi
    Mazzaferro, Vincenzo
    de Braud, Filippo
    Niger, Monica
    JAMA NETWORK OPEN, 2024, 7 (01)
  • [10] NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
    Ferdinando De Vita
    Jole Ventriglia
    Antonio Febbraro
    Maria Maddalena Laterza
    Alessio Fabozzi
    Beatrice Savastano
    Angelica Petrillo
    Anna Diana
    Guido Giordano
    Teresa Troiani
    Giovanni Conzo
    Gennaro Galizia
    Fortunato Ciardiello
    Michele Orditura
    BMC Cancer, 16
12345